The Johns Hopkins University received a $436,695 Project Grant award from the National Eye Institute (NEI) Vision Research program (CFDA 93.867) with a start date of July 1, 2024 and an end date of June 30, 2028. The award will fund research to develop a new hypotonic gelling eye drop formulation for effectively delivering drugs, such as the HIF-1 inhibitor acriflavine, to the posterior segment of the eye. This research aims to create a non-invasive, self-administered treatment option for neovascular age-related macular degeneration (nAMD) and other ocular diseases with neovascular complications, which currently rely on frequent intravitreal injections. The project will optimize the eye drop formulation properties, assess maximum tolerated dose and efficacy in animal models, and evaluate ocular pharmacokinetics and biocompatibility in rabbits. If successful, this research could lead to a first-of-its-kind eye drop treatment for nAMD.
Generated 3/4/25, 5:28 AM